These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 9510501)
1. Synergistic interaction of selected marine animal anticancer drugs against human diffuse large cell lymphoma. Mohammad RM; Pettit GR; Almatchy VP; Wall N; Varterasian M; Al-Katib A Anticancer Drugs; 1998 Feb; 9(2):149-56. PubMed ID: 9510501 [TBL] [Abstract][Full Text] [Related]
2. Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1. Mohammad RM; Varterasian ML; Almatchy VP; Hannoudi GN; Pettit GR; Al-Katib A Clin Cancer Res; 1998 May; 4(5):1337-43. PubMed ID: 9607595 [TBL] [Abstract][Full Text] [Related]
3. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model. Mohammad RM; Wall NR; Dutcher JA; Al-Katib AM Clin Cancer Res; 2000 Dec; 6(12):4950-6. PubMed ID: 11156256 [TBL] [Abstract][Full Text] [Related]
4. A new tubulin polymerization inhibitor, auristatin PE, induces tumor regression in a human Waldenstrom's macroglobulinemia xenograft model. Mohammad RM; Limvarapuss C; Wall NR; Hamdy N; Beck FW; Pettit GR; Al-Katib A Int J Oncol; 1999 Aug; 15(2):367-72. PubMed ID: 10402249 [TBL] [Abstract][Full Text] [Related]
5. Modulation of cIAP-1 by novel antitubulin agents when combined with bryostatin 1 results in increased apoptosis in the human early pre-B acute lymphoblastic leukemia cell line Reh. Wall NR; Mohammad RM; Nabha SM; Pettit GR; Al-Katib AM Biochem Biophys Res Commun; 1999 Dec; 266(1):76-80. PubMed ID: 10581168 [TBL] [Abstract][Full Text] [Related]
6. Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts. Al-Katib AM; Smith MR; Kamanda WS; Pettit GR; Hamdan M; Mohamed AN; Chelladurai B; Mohammad RM Clin Cancer Res; 1998 May; 4(5):1305-14. PubMed ID: 9607591 [TBL] [Abstract][Full Text] [Related]
7. Bryostatin 1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma. Mohammad RM; Diwakaran H; Maki A; Emara MA; Pettit GR; Redman B; al-Katib A Leuk Res; 1995 Sep; 19(9):667-73. PubMed ID: 7564478 [TBL] [Abstract][Full Text] [Related]
8. Bax:Bcl-2 ratio modulation by bryostatin 1 and novel antitubulin agents is important for susceptibility to drug induced apoptosis in the human early pre-B acute lymphoblastic leukemia cell line, Reh. Wall NR; Mohammad RM; Al-Katib AM Leuk Res; 1999 Oct; 23(10):881-8. PubMed ID: 10573132 [TBL] [Abstract][Full Text] [Related]
9. Treatment of a de novo fludarabine resistant-CLL xenograft model with bryostatin 1 followed by fludarabine. Mohammad RM; Limvarapuss C; Hamdy N; Dutcher BS; Beck FW; Wall NR; Al-Katib AM Int J Oncol; 1999 May; 14(5):945-50. PubMed ID: 10200346 [TBL] [Abstract][Full Text] [Related]
10. The bcl-2 and p53 oncoproteins can be modulated by bryostatin 1 and dolastatins in human diffuse large cell lymphoma. Maki A; Diwakaran H; Redman B; al-Asfar S; Pettit GR; Mohammad RM; al-Katib A Anticancer Drugs; 1995 Jun; 6(3):392-7. PubMed ID: 7670136 [TBL] [Abstract][Full Text] [Related]
11. Bryostatin 1 induces differentiation and potentiates the antitumor effect of Auristatin PE in a human pancreatic tumor (PANC-1) xenograft model. Mohammad RM; Adsay NV; Philip PA; Pettit GR; Vaitkevicius VK; Sarkar FH Anticancer Drugs; 2001 Oct; 12(9):735-40. PubMed ID: 11593055 [TBL] [Abstract][Full Text] [Related]
12. Clonal preservation of human pancreatic cell line derived from primary pancreatic adenocarcinoma. Mohammad RM; Li Y; Mohamed AN; Pettit GR; Adsay V; Vaitkevicius VK; Al-Katib AM; Sarkar FH Pancreas; 1999 Nov; 19(4):353-61. PubMed ID: 10547195 [TBL] [Abstract][Full Text] [Related]
13. Potentiation of 2-chlorodeoxyadenosine activity by bryostatin 1 in the resistant chronic lymphocytic leukemia cell line (WSU-CLL): association with increased ratios of dCK/5'-NT and Bax/Bcl-2. Mohammad RM; Beck FW; Katato K; Hamdy N; Wall N; Al-Katib A Biol Chem; 1998 Oct; 379(10):1253-61. PubMed ID: 9820586 [TBL] [Abstract][Full Text] [Related]
14. The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow. Koutcher JA; Motwani M; Zakian KL; Li XK; Matei C; Dyke JP; Ballon D; Yoo HH; Schwartz GK Clin Cancer Res; 2000 Apr; 6(4):1498-507. PubMed ID: 10778982 [TBL] [Abstract][Full Text] [Related]
15. Phase I and correlative study of combination bryostatin 1 and vincristine in relapsed B-cell malignancies. Dowlati A; Lazarus HM; Hartman P; Jacobberger JW; Whitacre C; Gerson SL; Ksenich P; Cooper BW; Frisa PS; Gottlieb M; Murgo AJ; Remick SC Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5929-35. PubMed ID: 14676117 [TBL] [Abstract][Full Text] [Related]
16. Successful treatment of human Waldenström's macroglobulinemia with combination biological and chemotherapy agents. Mohammad RM; al-Katib A; Pettit GR; Sensenbrenner LL Cancer Res; 1994 Jan; 54(1):165-8. PubMed ID: 8261437 [TBL] [Abstract][Full Text] [Related]
17. Sequential treatment of human chronic lymphocytic leukemia with bryostatin 1 followed by 2-chlorodeoxyadenosine: preclinical studies. Mohammad RM; Katato K; Almatchy VP; Wall N; Liu KZ; Schultz CP; Mantsch HH; Varterasian M; al-Katib AM Clin Cancer Res; 1998 Feb; 4(2):445-53. PubMed ID: 9516935 [TBL] [Abstract][Full Text] [Related]
18. Dolastatin 10 and dolastatin 15: effects of two natural peptides on growth and differentiation of leukemia cells. Steube KG; Grunicke D; Pietsch T; Gignac SM; Pettit GR; Drexler HG Leukemia; 1992 Oct; 6(10):1048-53. PubMed ID: 1405759 [TBL] [Abstract][Full Text] [Related]
19. I-kappa-kinase-2 (IKK-2) inhibition potentiates vincristine cytotoxicity in non-Hodgkin's lymphoma. Al-Katib A; Arnold AA; Aboukameel A; Sosin A; Smith P; Mohamed AN; Beck FW; Mohammad RM Mol Cancer; 2010 Sep; 9():228. PubMed ID: 20809973 [TBL] [Abstract][Full Text] [Related]
20. An orthotopic model of human pancreatic cancer in severe combined immunodeficient mice: potential application for preclinical studies. Mohammad RM; Al-Katib A; Pettit GR; Vaitkevicius VK; Joshi U; Adsay V; Majumdar AP; Sarkar FH Clin Cancer Res; 1998 Apr; 4(4):887-94. PubMed ID: 9563882 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]